In their quest for a cancer cure, researchers at the Duke Cancer Institute made a serendipitous discovery — a molecule necessary for cheaper and greener ways to produce nylon.
The finding, described in the journal Nature Chemical Biology, arose from an intriguing notion that some of the genetic and chemical changes in cancer tumors might be harnessed for beneficial uses.
“In our lab, we study genetic changes that cause healthy tissues to go bad and grow into tumors. The goal of this research is to understand how the tumors develop in order to design better treatments,” said Zachary J. Reitman, Ph.D., an associate in research at Duke and lead author of the study. “As it turns out, a bit of information we learned in that process paves the way for a better method to produce nylon.”
Nylon is a ubiquitous material, used in carpeting, upholstery, auto parts, apparel and other products. A key component for its production is adipic acid, which is one of the most widely used chemicals in the world. Currently, adipic acid is produced from fossil fuel, and the pollution released from the refinement process is a leading contributor to global warming.
Reitman said he and colleagues delved into the adipic acid problem based on similarities between cancer research techniques and biochemical engineering. Both fields rely on enzymes, which are molecules that convert one small chemical to another. Enzymes play a major role in both healthy tissues and in tumors, but they are also used to convert organic matter into synthetic materials such as adipic acid.
One of the most promising approaches being studied today for environmentally friendly adipic acid production uses a series of enzymes as an assembly line to convert cheap sugars into adipic acid. However, one critical enzyme in the series, called a 2-hydroxyadipate dehydrogenase, has never been produced, leaving a missing link in the assembly line.
This is where the cancer research comes in. In 2008 and 2009, Duke researchers, including Hai Yan, M.D., PhD., identified a genetic mutation in glioblastomas and other brain tumors that alters the function of an enzyme known as an isocitrate dehydrogenase.
Reitman and colleagues had a hunch that the genetic mutation seen in cancer might trigger a similar functional change to a closely related enzyme found in yeast and bacteria (homoisocitrate dehydrogenase), which would create the elusive 2-hydroxyadipate dehydrogenase necessary for “green” adipic acid production.
They were right. The functional mutation observed in cancer could be constructively applied to other closely related enzymes, creating a beneficial outcome – in this case the missing link that could enable adipic acid production from cheap sugars. The next step will be to scale up the overall adipic acid production process, which remains a considerable undertaking.
“It’s exciting that sequencing cancer genomes can help us to discover new enzyme activities,” Reitman said. “Even genetic changes that occur in only a few patients could reveal useful new enzyme functions that were not obvious before.”
Yan, a professor in the Department of Pathology and senior author of the study, said the research demonstrates how an investment in medical research can be applied broadly to solve other significant issues of the day.
“This is the result of a cancer researcher thinking outside the box to produce a new enzyme and create a precursor for nylon production,” Yan said. “Not only is this discovery exciting, it reaffirms the commitment we should be making to science and to encouraging young people to pursue science.”
In addition to Reitman and Yan, study authors include Bryan D. Choi, Ivan Spasojevic, Darell D. Bigner and John H. Sampson.
The work was supported with funds from the National Institutes of Health (R01 CA1403160). The authors are listed on a patent that is pending related to the mutated enzymes.
Duke University Medical Center